The study aims to evaluate how 19-hydroxybufalin affects gastric cancer cell growth and its potential mechanisms.
Investigated the effects of 19-hydroxybufalin on gastric cancer cells
Analyzed the impact on cellular proliferation
Targeted the phospholipase PLPP2 for metabolic changes
19-hydroxybufalin significantly inhibits the proliferation of gastric cancer cells
PLPP2 is identified as a potential therapeutic target
Metabolic reprogramming is altered in response to treatment
Abstract
19-H exerts its antigastric cancer effect by targeting PLPP2 and remodeling the metabolic network. PLPP2 may represent a novel therapeutic target for gastric cancer.